Restricted accessResearch articleFirst published online 2019-11
Treatment with Stem Cells from Human Exfoliated Deciduous Teeth and Their Derived Conditioned Medium Improves Retinal Visual Function and Delays the Degeneration of Photoreceptors
Retinitis pigmentosa (RP) is a hereditary disease characterized by degeneration and the loss of photoreceptors. Stem cell-based therapy has emerged as a promising strategy for treating RP. Stem cells from exfoliated deciduous teeth (SHEDs), a type of mesenchymal stem cell from human exfoliated deciduous teeth, have the potential to differentiate into photoreceptor-like cells under specific induction in vitro. It has been confirmed that through paracrine secreta, SHEDs exert neurotrophic, angiogenic, immunoregulatory, and antiapoptotic functions in injured tissues. This study was designed to determine whether retinal-differentiated SHEDs and the conditioned medium derived from SHEDs (SHEDs-CM) have therapeutic effects in a mouse model of RP. The results showed that both SHEDs and SHEDs-CM improved electroretinogram responses, ameliorated photoreceptor degeneration, and maintained the structure of the outer segments of photoreceptors. The therapeutic effects were related to antiapoptotic activity of SHEDs and SHEDs-CM. Thus, SHEDs may be a promising stem cell source for treating retinal degeneration.
Get full access to this article
View all access options for this article.
References
1.
HartongDT, BersonEL and DryjaTP. (2006). Retinitis pigmentosa. Lancet, 368:1795–1809.
2.
MilamAH, LiZY and FarissRN. (1998). Histopathology of the human retina in retinitis pigmentosa. Prog Retin Eye Res, 17:175–205.
3.
GroverS, FishmanGA, AndersonRJ, TozattiMSV, HeckenlivelyJR, WeleberRG, EdwardsAO and BrownJ. (1999). Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology, 106:1780–1785.
4.
HoAC, HumayunMS, DornJD, da CruzL, DagnelieG, HandaJ, BaraleP-O, SahelJ-A, StangaPE, et al. (2015). Long-term results from an epiretinal prosthesis to restore sight to the blind. Ophthalmology, 122:1547–1554.
5.
RussellS, BennettJ, WellmanJA, ChungDC, YuZ-F, TillmanA, WittesJ, PappasJ, ElciO, et al. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 390:849–860.
6.
Miraldi UtzV, CoussaRG, AntakiF and TraboulsiEI. (2018). Gene therapy for RPE65-related retinal disease. Ophthalmic Genet, 39:671–677.
7.
KlassenH. (2016). Stem cells in clinical trials for treatment of retinal degeneration. Expert Opin Biol Ther, 16:7–14.
8.
KaplanHJ, TezelTH, BergerAS, WolfML and DelPrioreLV. (1997). Human photoreceptor transplantation in retinitis pigmentosa—a safety study. Arch Ophthalmol, 115:1168–1172.
9.
DasT, del CerroM, JalaliS, RaoVS, GullapalliVK, LittleC, LoretoDA, SharmaS, SreedharanA, del CerroC and RaoGN. (1999). The transplantation of human fetal neuroretinal cells in advanced retinitis pigmentosa patients: results of a long-term safety study. Exp Neurol, 157:58–68.
10.
RadtkeND, AramantRB, SeilerM and PetryHM. (1999). Preliminary report: indications of improved visual function after retinal sheet transplantation in retinitis pigmentosa patients. Am J Ophthalmol, 128:384–387.
11.
MacLarenRE, PearsonRA, MacNeilA, DouglasRH, SaltTE, AkimotoM, SwaroopA, SowdenJC and AliRR. (2006). Retinal repair by transplantation of photoreceptor precursors. Nature, 444:203–207.
12.
AssawachananontJ, MandaiM, OkamotoS, YamadaC, EirakuM, YonemuraS, SasaiY and TakahashiM. (2014). Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. Stem Cell Rep, 2:662–674.
13.
Gonzalez-CorderoA, KruczekK, NaeemA, FernandoM, KlocM, RibeiroJ, GohD, DuranY, BlackfordSJI, et al. (2017). Recapitulation of human retinal development from human pluripotent stem cells generates transplantable populations of cone photoreceptors. Stem Cell Rep, 9:820–837.
MiuraM, GronthosS, ZhaoM, LuB, FisherLW, RobeyPG and ShiS. (2003). SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A, 100:5807–5812.
16.
KerkisI, KerkisA, DozortsevD, Stukart-ParsonsGC, Gomes MassironiSM, PereiraLV, CaplanAI and CerrutiHF. (2006). Isolation and characterization of a population of immature dental pulp stem cells expressing OCT-4 and other embryonic stem cell markers. Cells Tissues Organs, 184:105–116.
17.
YamazaT, KentaroA, ChenC, LiuY, ShiY, GronthosS, WangS and ShiS. (2010). Immunomodulatory properties of stem cells from exfoliated deciduous teeth. Stem Cell Res Ther, 1:5.
18.
InoueT, SugiyamaM, HattoriH, WakitaH, WakabayashiT and UedaM. (2013). Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A, 19:24–29.
19.
TaghipourZ, KarbalaieK, KianiA, NiapourA, BahramianH, Nasr-EsfahaniMH and BaharvandH. (2012). Transplantation of undifferentiated and induced human exfoliated deciduous teeth-derived stem cells promote functional recovery of rat spinal cord contusion injury model. Stem Cells Dev, 21:1794–1802.
20.
Sugimura-WakayamaY, KatagiriW, OsugiM, KawaiT, OgataK, SakaguchiK and HibiH. (2015). Peripheral nerve regeneration by secretomes of stem cells from human exfoliated deciduous teeth. Stem Cells Dev, 24:2687–2699.
21.
SugiyamaM, IoharaK, WakitaH, HattoriH, UedaM, MatsushitaK and NakashimaM. (2011). Dental pulp-derived CD31(−)/CD146(−) side population stem/progenitor cells enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A, 17:1303–1311.
22.
ShimojimaC, TakeuchiH, JinS, ParajuliB, HattoriH, SuzumuraA, HibiH, UedaM and YamamotoA. (2016). Conditioned medium from the stem cells of human exfoliated deciduous teeth ameliorates experimental autoimmune encephalomyelitis. J Immunol, 196:4164–4171.
23.
LiX, XieJ, ZhaiY, FangT, RaoN, HuS, YangL, ZhaoY, WangY and GeL. (2019). Differentiation of stem cells from human exfoliated deciduous teeth into retinal photoreceptor-like cells and their sustainability in vivo. Stem Cells Int, 2019:2562981.
24.
WrightAF, ChakarovaCF, Abd El-AzizMM and BhattacharyaSS. (2010). Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet, 11:273–284.
25.
HongDH, PawlykBS, ShangJ, SandbergMA, BersonEL and LiT. (2000). A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3). Proc Natl Acad Sci U S A, 97:3649–3654.
26.
DingSLS, KumarS and MokPL. (2017). Cellular reparative mechanisms of mesenchymal stem cells for retinal diseases. Int J Mol Sci, 18:pii:E1406.
27.
InoueY, IriyamaA, UenoS, TakahashiH, KondoM, TamakiY, AraieM and YanagiY. (2007). Subretinal transplantation of bone marrow mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal degeneration. Exp Eye Res, 85:234–241.
28.
TzameretA, SherI, BelkinM, TrevesAJ, MeirA, NaglerA, Levkovitch-VerbinH, RotenstreichY and SolomonAS. (2015). Epiretinal transplantation of human bone marrow mesenchymal stem cells rescues retinal and vision function in a rat model of retinal degeneration. Stem Cell Res, 15:387–394.
29.
TzameretA, SherI, BelkinM, TrevesAJ, MeirA, NaglerA, Levkovitch-VerbinH, BarshackI, RosnerM and RotenstreichY. (2014). Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res, 118:135–144.
30.
LuB, WangS, GirmanS, McGillT, RagagliaV and LundR. (2010). Human adult bone marrow-derived somatic cells rescue vision in a rodent model of retinal degeneration. Exp Eye Res, 91:449–455.
31.
AthanasiouD, AguilaM, BellinghamJ, LiW, McCulleyC, ReevesPJ and CheethamME. (2018). The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res, 62:1–23.
32.
LiuX, ZhangY, HeY, ZhaoJ and SuG. (2015). Progress in histopathologic and pathogenetic research in a retinitis pigmentosa model. Histol Histopathol, 30:771–779.
33.
MaguireAM, SimonelliF, PierceEA, PughENJr., MingozziF, BennicelliJ, BanfiS, MarshallKA, TestaF, et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 358:2240–2248.
34.
Medawar PB. (1948). Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol, 29:58–69.
35.
Streilein JW. (1995). Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond) 9, (Pt 2)::236–240.
36.
Marcus Frank HW. (1996). Cellular reactions at the lesion site after crushing of the rat optic nerve. Glia, 16:227–240.
37.
BenharI, LondonA and SchwartzM. (2012). The privileged immunity of immune privileged organs: the case of the eye. Front Immunol, 3:296.
38.
LohanP, TreacyO, MorcosM, DonohoeE, O'DonoghueY, RyanAE, EllimanSJ, RitterT and GriffinMD. (2018). Interspecies incompatibilities limit the immunomodulatory effect of human mesenchymal stromal cells in the rat. Stem Cells, 36:1210–1215.
39.
TreacyO, O'FlynnL, RyanAE, MorcosM, LohanP, SchuS, WilkM, FahyG, GriffinMD, NosovM and RitterT. (2014). Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation. Am J Transplant, 14:2023–2036.
40.
PanD, ChangX, XuM, ZhangM, ZhangS, WangY, LuoX, XuJ, YangX and SunX. (2019). UMSC-derived exosomes promote retinal ganglion cells survival in a rat model of optic nerve crush. J Chem Neuroanat, 96:134–139.
41.
MeadB and TomarevS. (2017). Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. Stem Cells Transl Med, 6:1273–1285.
42.
JohnsonTV, DeKorverNW, LevasseurVA, OsborneA, TassoniA, LorberB, HellerJP, VillasmilR, BullND, MartinKR and TomarevSI. (2014). Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain 137, (Pt 2)::503–519.
43.
MoisseievE, AndersonJD, OltjenS, GoswamiM, ZawadzkiRJ, NoltaJA and ParkSS. (2017). Protective effect of intravitreal administration of exosomes derived from mesenchymal stem cells on retinal ischemia. Curr Eye Res, 42:1358–1367.
44.
BiB, SchmittR, IsrailovaM, NishioH and CantleyLG. (2007). Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol, 18:2486–2496.
45.
XingL, CuiR, PengL, MaJ, ChenX, XieRJ and LiB. (2014). Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury. Stem Cells Res Ther, 5:101.
46.
BaraniakPR and McDevittTC. (2010). Stem cell paracrine actions and tissue regeneration. Regen Med, 5:121–143.
47.
FerreiraJR, TeixeiraGQ, SantosSG, BarbosaMA, Almeida-PoradaG and GoncalvesRM. (2018). Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Front Immunol, 9:2837.
48.
MansoorH, OngHS, RiauAK, StanzelTP, MehtaJS and YamGH. (2019). Current trends and future perspective of mesenchymal stem cells and exosomes in corneal diseases. Int J Mol Sci, 20:pii:E2853.
49.
Lopez-VerrilliMA, CaviedesA, CabreraA, SandovalS, WynekenU and KhouryM. (2016). Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. Neuroscience, 320:129–139.
50.
KlingebornM, DismukeWM, Bowes RickmanC and StamerWD. (2017). Roles of exosomes in the normal and diseased eye. Prog Retin Eye Res, 59:158–177.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
